A 32-year-old male is rushed to the ER. An hour ago, he was playing football with his friends, as he does every week. No smoking. Barely drinks. No family history anyone knew about. He is 32 years old, and his heart is attacking him. He is not an anomaly anymore. He is a pattern. According to an extensive study spanning 16 years, the rate of having a heart attack in people under 40 has been increasing by 2 percent annually, a trend showing no signs of slowing. In the U.S., in-hospital deaths from severe heart attacks rose 57 percent in adults aged 18-54 between 2011 and 2022. This is not an epidemic affecting only the U.S., as the increasing trend has also been reported across the globe. Data from 2022 showed that, in India, a quarter of all heart attacks in men occur under 40, with more than 30,000 deaths the same year. The British Heart Foundation notes that at least 12 young individuals under 35 die weekly in the U.K. from undiagnosed heart conditions, and premature heart disease deaths in 2022 were the highest recorded in over a decade, reversing nearly 60 years of progress. To make matters worse, young patients are paradoxically disadvantaged by their own age, as neither they nor their doctors readily suspect the heart, leading to delayed diagnosis and treatment.

So what is driving a generation raised on fitness apps and health awareness straight into emergency rooms then? The answer is not as simple as a bad diet and a sedentary lifestyle, and that oversimplification is itself part of the problem. The usual suspects are well known: obesity, hypertension, diabetes, and high cholesterol. But the existence of these conditions is not exclusive to this generation; the problem is that they are appearing earlier, progressing insidiously and going undetected for longer.

Chronic stress, once considered a phenomenon of adulthood, has become a defining feature of today’s youth. Digital overexposure, financial instability, and the relentless comparisons of social media keep an entire generation in a sustained state of psychological strain. Physiologically, chronic stress activates the hypothalamic-pituitary-adrenal axis, leading to sustained release of cortisol and catecholamines. Over time, this dysregulation contributes to immune imbalance, low-grade inflammation, and endothelial dysfunction, accelerating atherosclerotic plaque development. These processes may accumulate silently over months to years, gradually reshaping vascular biology. In this sense, the coronary arteries of a chronically stressed 25-year-old may biologically resemble those of someone far older. A meta-analysis of 33 studies involving over 43,000 participants found that individuals with elevated cortisol levels faced a 60 percent higher risk of cardiovascular disease compared to those with lower cortisol levels. Additionally, work stress alone was associated with a threefold higher risk of a cardiovascular event.

Compounding this further is a crisis that shares both its roots and its consequences with chronic stress: sleep deprivation. Once dismissed as a student cliche, insufficient and ineffective sleep has quietly become the norm for many young adults, normalized and at times even worn as a badge of productivity. During sleep, heart rate and blood pressure normally fall, while vascular repair processes are activated. Sleep deprivation disrupts this pattern, blunting the nocturnal blood pressure dip and maintaining sympathetic nervous system activity into the night. Over time, this is associated with endothelial dysfunction even in otherwise healthy young adults. It also impairs glucose tolerance, increases cortisol levels, and reduces leptin secretion, reinforcing metabolic and inflammatory pathways already activated by chronic stress. Together, sleep deprivation and psychological stress do not merely coexist; they amplify one another’s physiological impact. The cardiovascular risk associated with sleep problems is significantly more pronounced in adults under 50, precisely the population currently sleeping the least; and sleeping five hours or less per night has been associated with a 51 percent increased risk of developing hypertension in younger adults aged 32 to 59. Your heart does not treat lost sleep as a minor inconvenience. It treats it as a chronic injury.

Less frequently discussed, but increasingly documented, is the cardiovascular toll associated with energy drink consumption among young people. These beverages are widely available and only loosely regulated compared with pharmacological agents, despite containing potent stimulants such as caffeine at concentrations that would be concerning in any clinical context. Energy drinks are consumed by 30 to 50 percent of the young population in the United States alone, and the global market is valued at nearly $74 billion, still growing. These beverages push the heart into a sustained fight or flight mode. Caffeine does this by blocking adenosine receptors, essentially removing the brain’s natural brake on heart rate and vascular tone, triggering a cascade of catecholamine release that simultaneously raises heart rate, blood pressure, and the heart’s demand for oxygen.

In most healthy young people, most of the time, this passes without consequence. The problem emerges in susceptible settings: repeated daily exposure, an undetected coronary abnormality, or the combination with other stressors like sleep deprivation or smoking. In those circumstances, the gap between how much oxygen the heart demands and how much the coronary arteries can deliver becomes dangerous. Energy drinks also destabilize the heart’s electrical system by shortening refractory periods and increasing the excitability of cardiac muscle cells. This is why most documented acute events linked to energy drink consumption involve arrhythmias rather than the classic blocked artery heart attack. The long-term risk is more subtle. Repeated sympathetic surges likely contribute to gradual endothelial dysfunction over time. But the immediate danger is electrical: a heart rhythm that should self-terminate, but doesn’t.

The risk becomes more pronounced when energy drinks are mixed with alcohol, a combination that is common because it feels deceptively manageable. Alcohol dulls our perception of stimulation, so the body’s actual physiological stress goes unnoticed. Heart rate and blood pressure may already be elevated from the caffeine load, but the individual feels less intoxicated than they actually are. That mismatch is important as it often leads to drinking more alcohol, more caffeine, or both, straining the cardiovascular system more without even clear awareness of it. This is not just theoretical. There are reported cases where the combination has been followed by serious cardiac rhythm disturbances and acute cardiovascular events in young adults, including fatal outcomes. A systematic review that screened over 1,400 studies found a fairly consistent pattern: energy drinks increase heart rate, raise both systolic and diastolic blood pressure, and can prolong the QTc interval on ECG. That last finding especially matters because QTc prolongation reflects a change in the heart’s electrical recovery phase, and in certain settings it can increase vulnerability to dangerous rhythm disturbances. Across the literature, this wasn’t an isolated finding as it showed up repeatedly, even if the magnitude varied between studies.

Unfortunately, the cardiovascular burden of what young people consume does not end with energy drinks, as these substances often do not exist in isolation. In many cases, they share demographics and social settings. Smoking’s cardiovascular consequences are well established and perhaps need little introduction. Nicotine drives sympathetic activation and sustained vasoconstriction, carbon monoxide displaces oxygen from hemoglobin thereby reducing myocardial oxygen delivery, and the chronic oxidative stress and inflammation generated by combustion products accelerates atherosclerosis through mechanisms now documented over decades of extensive research.

What deserves closer attention is what has quietly replaced cigarettes in the hands of a younger generation: vaping. Vaping was marketed on a simple premise. No combustion, therefore safer. Sounds plausible, but that premise, however, ignored something fundamental: the cardiovascular toxicity of nicotine has absolutely nothing to do with how it is delivered. Modern pod devices deliver nicotine at concentrations equivalent to or sometimes exceeding cigarettes, producing the same sympathetic surge, the same endothelial damage, and the same hemodynamic stress on the coronary vasculature. In addition to already dangerous nicotine, the aerosol itself carries ultrafine particles that deposit directly in coronary vessels, provoking local inflammatory responses. Flavoring compounds such as acrolein and diacetyl carry independent endothelial toxicity that is only beginning to be characterized. The result is a product that may avoid the tar of combustion while retaining most of the cardiovascular harm, wrapped in a form that a generation of young people adopted before the evidence had time to catch up. People who vaped showed cardiovascular function changes comparable to smokers despite being 15 years younger, and after controlling for other risk factors, e-cigarette users were 34 percent more likely to have a heart attack and 25 percent more likely to have coronary artery disease. A separate study of 175,667 participants found that e-cigarette users were 19 percent more likely to develop heart failure compared to never-users.

Of all the substances reshaping the cardiovascular map of young people, two stand out not only for their toxicity but for how casually they are now encountered: cocaine and cannabis. What makes this more alarming is that both are increasingly found laced with even deadlier drugs like fentanyl.

Similar to the earlier situation with smoking and vaping, cocaine’s dangers are not surprising and can’t be overstated. Cocaine exerts its cardiovascular toxicity primarily through massive catecholamine release by blocking the reuptake of norepinephrine and dopamine simultaneously, flooding the system with sympathetic drive. The result is acute and dramatic; heart rate surges, blood pressure spikes, and coronary arteries go into vasospasm. However, unlike the gradual endothelial damage of chronic stress or sleep deprivation, cocaine can trigger a myocardial infarction within minutes of use in arteries that are otherwise completely clean. Particularly dangerous is the combination with alcohol. A compound called cocaethylene that the liver produces when cocaine is mixed with alcohol consumption independently causes cardiac toxicity that outlasts either compound alone. A nationally representative study of adults aged 18 to 45 in the U.S. found that frequent cocaine users had nearly seven times the likelihood of a non-fatal heart attack compared to non-users, and estimated that approximately one in every four heart attacks in young people in this age group was attributable to cocaine use. When combined with alcohol, the production of cocaethylene increases the risk of sudden death by 18 to 25 times compared to cocaine usage alone.

With cocaine, the danger is understood. With cannabis, the danger lies precisely in the widespread belief that there is none. Cannabis exerts its cardiovascular effects primarily through cannabinoid receptors, particularly CB1 receptors, found throughout the heart and vascular system. Acute consumption triggers an immediate increase in heart rate, sometimes by 20 to 50 beats per minute, while simultaneously causing erratic fluctuations in blood pressure. This creates a mismatch between myocardial oxygen demand and supply that, in susceptible individuals, can readily tip into ischemia. Beyond the acute hemodynamic effects, cannabis also promotes coronary vasospasm through mechanisms that partially overlap with but are distinct from those of cocaine. It also activates platelet aggregation and induces a pro-inflammatory and pro-thrombotic state: the same constellation of changes that chronic stress and sleep deprivation build slowly over months, but arrive acutely with each use. The precise mechanisms are not yet fully characterized. Cannabis research has historically been constrained by legal and funding barriers, meaning the science is younger than the habit itself. That gap between how long people have been using it and how little we formally understand about its long-term cardiovascular effects is itself a cause for concern. In the U.S., daily cannabis use is now 15 times higher than it was in 1992, and more adults report daily cannabis use than daily alcohol use. A retrospective study of over 4.6 million adults published in the Journal of the American College of Cardiology found that cannabis users under 50 with no prior cardiovascular disease, normal blood pressure, normal cholesterol and no diabetes were over six times more likely to suffer a heart attack, four times more likely to have an ischemic stroke, twice as likely to develop heart failure and three times more likely to experience major adverse cardiovascular events. A separate meta-analysis pooling data from 12 studies covering over 75 million people confirmed a 50 percent increased risk of heart attack among cannabis users overall, a finding consistent across vastly different study populations.

Not every young heart attack has a lifestyle explanation. Some are written into the genome even before the first breath is taken. One of these cases is familial hypercholesterolemia. FH is caused by mutations primarily in the low-density lipoprotein (LDL) receptor gene. LDL is primarily known as “bad” cholesterol. As a result of this mutation the liver cannot adequately clear LDL from circulation. The result is not mildly elevated cholesterol. It is severely elevated LDL from birth, relentlessly depositing in arterial walls for decades before any symptom appears. The atherosclerosis that a normal person might develop over 60 years of poor lifestyle choices, an untreated FH patient may accumulate by their 30s or 40s through no fault of their own. FH affects at least 1 in 500 people worldwide, making it more common than cystic fibrosis, Marfan syndrome and Down syndrome combined. Untreated men with FH carry a 50 percent risk of a fatal or non-fatal coronary event by age 50. Untreated women carry a 30 percent risk by age 60. Approximately 5 percent of all heart attacks in people under 60 and as many as 20 percent of heart attacks in people under 45 are attributable to FH. Among young adults who suffer a heart attack, clinically defined FH is present in nearly 1 in 10 patients. Despite affecting potentially millions of people worldwide, fewer than 10 percent of FH patients in the United States have been properly diagnosed; and in many cases the diagnosis is made only after the first cardiac event has already occurred. Early diagnosis and treatment can reduce the risk of coronary artery disease in FH patients by approximately 80 percent. FH is not rare. It is unrecognized. And that distinction has cost lives that treatment could have saved.

FH reveals how genetics can silently load a weapon over decades. Spontaneous coronary artery dissection (SCAD) reveals something different: how medicine can look directly at a young woman having a heart attack and still fail to recognize what it is seeing. Unlike every cause discussed so far, SCAD has nothing to do with atherosclerosis, lifestyle, or the gradual accumulation of risk. Instead, the wall of the coronary artery itself spontaneously tears creating a false channel, or intramural hematoma, that compresses the true lumen from the outside and cuts off blood flow to the heart muscle. The artery is not blocked by plaque but rather being strangled by its own wall. The triggers are varied: intense physical exertion, emotional stress, hormonal fluctuations, the peripartum period; but in many cases no identifiable trigger is found at all. What makes SCAD particularly dangerous beyond its mechanism is what a misdiagnosis sets in motion. Unlike atherosclerotic MI where stenting is standard practice, intervening in SCAD with the same protocol can actively worsen outcomes. Getting the diagnosis wrong does not simply mean missing it; it means treating it with tools designed for a fundamentally different disease. SCAD predominantly affects women, approximately 90 percent of cases, typically in their 40s and 50s, and most commonly with few or no traditional cardiovascular risk factors. While it accounts for less than 5 percent of all acute coronary syndrome cases overall, it accounts for up to a third of all myocardial infarctions in women under the age of 50. It is also the most common cause of pregnancy-associated myocardial infarction, responsible for 43 percent of MI cases in that setting. The American Heart Association has stated directly that missed diagnoses of SCAD are driven by low clinical suspicion of acute coronary syndrome in young women, even when classic symptoms are present. The widespread assumption among clinicians that young women are at low risk of cardiac events leads to underuse of the very investigations that would reveal SCAD. The diagnosis is not being missed because the condition is rare. It is being missed because nobody is looking for it. That assumption has a body count.

On the topic of increasing heart attacks in young people, these are not the only mechanisms at play. Post-COVID cardiovascular effects, hypertrophic cardiomyopathy in young athletes, microplastics accumulating in arterial walls; the list continues to grow as research catches up with a problem that medicine has been slow to take seriously. The 32-year-old on the football pitch was not a tragedy waiting to happen. He was a warning that went unread.

Samir Mammadov is a medical student.